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Prevention and Control of Influenza:
Recommendations of the Advisory Committee on
Immunization Practices (ACIP)
Summary
These recommendations update information concerning the vaccine and an-
tiviral agents available for controlling influenza during the 1997–98 influenza
season (superseding MMWR 1996;45[No. RR-5]:1–24). The principal changes in-
clude information about a) the influenza virus strains included in the trivalent
vaccine for 1997–98, b) the vaccination of pregnant and breastfeeding women,
and c) side effects and adverse reactions.
INTRODUCTION
Influenza A viruses are classified into subtypes on the basis of two surface anti-
gens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin
(H1, H2, and H3) and two subtypes of neuraminidase (N1 and N2) are recognized
among influenza A viruses that have caused widespread human disease. Immunity to
these antigens—especially to the hemagglutinin—reduces the likelihood of infection
and lessens the severity of disease if infection occurs. Infection with a virus of one
subtype confers little or no protection against viruses of other subtypes. Furthermore,
over time, antigenic variation (antigenic drift) within a subtype may be so marked that
infection or vaccination with one strain may not induce immunity to distantly related
strains of the same subtype. Although influenza B viruses have shown more antigenic
stability than influenza A viruses, antigenic variation does occur. For these reasons,
major epidemics of respiratory disease caused by new variants of influenza continue
to occur. The antigenic characteristics of circulating strains provide the basis for se-
lecting the virus strains included in each year’s vaccine.
Typical influenza illness is characterized by abrupt onset of fever, myalgia, sore
throat, and nonproductive cough. Unlike other common respiratory illnesses, influ-
enza can cause severe malaise lasting several days. More severe illness can result if
either primary influenza pneumonia or secondary bacterial pneumonia occurs. During
influenza epidemics, high attack rates of acute illness result in both increased
numbers of visits to physicians’ offices, walk-in clinics, and emergency rooms and
increased hospitalizations for management of lower respiratory tract complications.
Elderly persons and persons with underlying health problems are at increased risk
for complications of influenza. If they become ill with influenza, such members of
high-risk groups (see Groups at Increased Risk for Influenza-Related Complications)
are more likely than the general population to require hospitalization. During major
epidemics, hospitalization rates for persons at high risk may increase twofold to five-
fold, depending on the age group. Previously healthy children and younger adults
also may require hospitalization for influenza-related complications, but the relative
increase in their hospitalization rates is less than for persons who belong to high-risk
groups.
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An increase in mortality further indicates the impact of influenza epidemics. In-
creased mortality results not only from influenza and pneumonia but also from
cardiopulmonary and other chronic diseases that can be exacerbated by influenza. An
estimated >20,000 influenza-associated deaths occurred during each of nine different
U.S. epidemics from 1972–73 to 1991–92, and >40,000 influenza-associated deaths oc-
curred during each of four of these epidemics. More than 90% of the deaths attributed
to pneumonia and influenza occurred among persons aged ≥65 years.
The number of elderly persons in the U.S. population is increasing, as well as the
number of persons aged <65 years at increased risk for influenza-related complica-
tions.  Longer life expectancy for a) organ-transplant recipients, b) neonates in
intensive-care units, and c) persons who have cystic fibrosis and acquired immunode-
ficiency syndrome (AIDS) results in a higher survival rate for younger persons at high
risk for influenza.
Influenza vaccine campaigns are targeted to approximately 32 million persons
aged ≥65 years and 27 million to 31 million persons aged <65 years who are at high
risk for influenza-associated complications. National health objectives for the year
2000 include vaccination of at least 60% of persons at risk for severe influenza-related
illness.
Influenza vaccination levels among persons aged ≥65 years increased substantially
from 1985 (23%) to 1994 (55%), although vaccination levels among persons aged <65
years at high risk for influenza are estimated to be <30%.  Possible reasons for the
increase in influenza vaccination levels, especially among persons aged ≥65 years,
include greater acceptance of preventive medical services by practitioners, increased
delivery and administration of vaccine by health-care providers and sources other
than physicians, and the initiation of Medicare reimbursement for influenza vaccina-
tion in 1993. 
OPTIONS FOR THE CONTROL OF INFLUENZA
In the United States, two measures are available that can reduce the impact
of influenza: immunoprophylaxis with inactivated (i.e., killed-virus) vaccine and
chemoprophylaxis or therapy with an influenza-specific antiviral drug (amantadine or
rimantadine). Vaccinating persons at high risk before the influenza season each year is
the most effective measure for reducing the impact of influenza. Vaccination can be
highly cost effective when it is a) directed at persons who are most likely to experience
complications or who are at increased risk for exposure and b) administered to per-
sons at high risk during hospitalizations or routine health-care visits before the
influenza season, thus making special visits to physicians’ offices or clinics unneces-
sary. When vaccine and epidemic strains of virus are well matched, achieving high
vaccination rates among persons living in closed settings (e.g., nursing homes and
other chronic-care facilities) can reduce the risk for outbreaks by inducing herd
immunity.
INACTIVATED VACCINE FOR INFLUENZA A AND B
Each year’s influenza vaccine contains three virus strains (usually two type A and
one type B) representing the influenza viruses that are likely to circulate in the United
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States in the upcoming winter. The vaccine is made from highly purified, egg-grown
viruses that have been made noninfectious (inactivated). Influenza vaccine rarely
causes systemic or febrile reactions. Whole-virus, subvirion, and purified-surface–
antigen preparations are available.
Most vaccinated children and young adults develop high postvaccination
hemagglutination-inhibition antibody titers. These antibody titers are protective
against illness caused by strains similar to those in the vaccine or the related variants
that may emerge during outbreak periods. Elderly persons and persons with certain
chronic diseases may develop lower postvaccination antibody titers than healthy
young adults and thus may remain susceptible to influenza-related upper respiratory
tract infection. However, even if such persons develop influenza illness despite vacci-
nation, the vaccine can be effective in preventing lower respiratory tract involvement
or other secondary complications, thereby reducing the risk for hospitalization and
death.
The effectiveness of influenza vaccine in preventing or attenuating illness varies,
depending primarily on the age and immunocompetence of the vaccine recipient and
the degree of similarity between the virus strains included in the vaccine and those
that circulate during the influenza season. When a good match exists between vaccine
and circulating viruses, influenza vaccine has been shown to prevent illness in ap-
proximately 70%–90% of healthy persons aged <65 years. In these circumstances,
studies also have indicated that the effectiveness of influenza vaccine in preventing
hospitalization for pneumonia and influenza among elderly persons living in settings
other than nursing homes or similar chronic-care facilities ranges from 30% to 70%.
Among elderly persons residing in nursing homes, influenza vaccine is most effec-
tive in preventing severe illness, secondary complications, and death. Studies of this
population have indicated that the vaccine can be 50%–60% effective in preventing
hospitalization and pneumonia and 80% effective in preventing death, even though
efficacy in preventing influenza illness may often be in the range of 30%–40% among
the frail elderly. Achieving a high rate of vaccination among nursing home residents
can reduce the spread of infection in a facility, thus preventing disease through herd
immunity.
RECOMMENDATIONS FOR THE USE OF INFLUENZA VACCINE
Influenza vaccine is strongly recommended for any person aged ≥6 months who—
because of age or underlying medical condition—is at increased risk for complications
of influenza. Health-care workers and others (including household members) in close
contact with persons in high-risk groups also should be vaccinated. In addition, influ-
enza vaccine may be administered to any person who wishes to reduce the chance of
becoming infected with influenza. The trivalent influenza vaccine prepared for the
1997–98 season will include A/Bayern/07/95-like (H1N1), A/Wuhan/359/95-like (H3N2),
and B/Beijing/184/93-like hemagglutinin antigens. For the A/Bayern/07/95-like,
A/Wuhan/ 359/95-like, and B/Beijing/184/93-like antigens, U.S. manufacturers will use
the antigenically equivalent strains A/Johannesburg/82/96(H1N1), A/Nanchang/933/95
(H3N2), and B/Harbin/07/94 because of their growth properties. Guidelines for the use
of vaccine among certain patient populations follow; dosage recommendations vary
according to age group (Table 1). 
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Although the current influenza vaccine can contain one or more of the antigens
administered in previous years, annual vaccination with the current vaccine is neces-
sary because immunity declines in the year following vaccination. Because the
1997–98 vaccine differs from the 1996–97 vaccine, supplies of 1996–97 vaccine should
not be administered to provide protection for the 1997–98 influenza season.
Two doses administered at least 1 month apart may be required for satisfactory
antibody responses among previously unvaccinated children aged <9 years; however,
studies of vaccines similar to those being used currently have indicated little or no
improvement in antibody response when a second dose is administered to adults dur-
ing the same season.
During recent decades, data on influenza vaccine immunogenicity and side effects
have been obtained for intramuscularly administered vaccine. Because recent influ-
enza vaccines have not been adequately evaluated when administered by other
routes, the intramuscular route is recommended. Adults and older children should be
vaccinated in the deltoid muscle and infants and young children in the anterolateral
aspect of the thigh.
TABLE 1. Influenza vaccine* dosage, by age group — United States, 1997–98 season
Age group Product† Dosage No. of doses Route§
6–35 mos Split virus only 0.25 mL 1 or 2¶   IM**
3– 8 yrs Split virus only 0.50 mL 1 or 2¶ IM
9–12 yrs Split virus only 0.50 mL 1 IM
 >12 yrs Whole or split virus 0.50 mL 1 IM
 *Contains 15 µg each of A/Bayern/07/95-like (H1N1), A/Wuhan/359/95-like (H3N2), and
B/Beijing/184/93-like hemagglutinin antigens in each 0.5 mL. For the A/Bayern/07/95-like,
A/Wuhan/359/95-like, and B/Beijing/184/93-like antigens, U.S. manufacturers will use the
antigenically equivalent strains A/Johannesburg/82/96(H1N1), A/Nanchang/933/95 (H3N2),
and B/Harbin/07/94 because of their growth properties. Manufacturers include: Connaught
Laboratories, Inc. (Fluzone whole or split); Evans Medical Ltd. (an affiliate of Medeva
Pharmaceuticals, Inc.) (Fluvirin purified surface antigen vaccine) and Wyeth-Ayerst
Laboratories (Flushield split). For further product information call Connaught, (800)
822-2463; Evans/Medeva, (800) 932-1950 or Wyeth-Ayerst, (800) 358-7443.
†Because of their decreased potential for causing febrile reactions, only split-virus vaccines
should be used for children. They may be labeled as “split,” “subvirion,” or “purified-
surface–antigen” vaccine. Immunogenicity and side effects of split- and whole-virus
vaccines are similar among adults when vaccines are administered at the recommended
dosage.
§For adults and children, the recommended site of vaccination is the deltoid muscle. The
preferred site for infants and young children is the anterolateral aspect of the thigh.
¶Two doses administered at least 1 month apart are recommended for children aged <9 years
who are receiving influenza vaccine for the first time.
**Intramuscular.
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TARGET GROUPS FOR SPECIAL VACCINATION PROGRAMS
Groups at Increased Risk for Influenza-Related Complications:
• Persons aged ≥65 years
• Residents of nursing homes and other chronic-care facilities that house persons
of any age who have chronic medical conditions
• Adults and children who have chronic disorders of the pulmonary or cardiovas-
cular systems, including children with asthma
• Adults and children who have required regular medical follow-up or hospitaliza-
tion during the preceding year because of chronic metabolic diseases (including
diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppres-
sion (including immunosuppression caused by medications)
• Children and teenagers (aged 6 months–18 years) who are receiving long-term
aspirin therapy and therefore might be at risk for developing Reye syndrome
after influenza
• Women who will be in the second or third trimester of pregnancy during the
influenza season
Influenza-associated excess mortality among pregnant women has not been
documented except during the pandemics of 1918–19 and 1957–58. However, be-
cause death-certificate data often do not indicate whether a woman was
pregnant at the time of death, studies conducted during interpandemic periods
may underestimate the impact of influenza in this population. Case reports and
limited studies suggest that pregnancy may increase the risk for serious medical
complications of influenza as a result of increases in heart rate, stroke volume
and oxygen consumption, decreases in lung capacity, and changes in immu-
nologic function. A recent study of the impact of influenza during 17
interpandemic influenza seasons documented that the relative risk of hospitaliza-
tion for selected cardiorespiratory conditions among pregnant women increased
from 1.4 during weeks 14–20 of gestation to 4.7 during weeks 37–42 compared
with rates among women who were 1–6 months postpartum. Women in their
third trimester of pregnancy were hospitalized at a rate comparable to that of
nonpregnant women who have high-risk medical conditions for whom influenza
vaccine has traditionally been recommended. Using data from this study, it was
estimated that an average of 1 to 2 hospitalizations among pregnant women
could be prevented for every 1,000 pregnant women immunized.
On the basis of these and other data that suggest that influenza infection may
cause increased morbidity in women during the second and third trimesters of
pregnancy, the Advisory Committee on Immunization Practices (ACIP) recom-
mends that women who will be beyond the first trimester of pregnancy (14
weeks’ gestation) during the influenza season be vaccinated.  Pregnant women
who have medical conditions that increase their risk for complications from influ-
enza should be vaccinated before the influenza season—regardless of the stage
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of pregnancy. Studies of influenza immunization of more than 2,000 pregnant
women have demonstrated no adverse fetal effects associated with influenza
vaccine; however, more data are needed. Because influenza vaccine is not a live
virus vaccine and major systemic reactions to it are rare, many experts consider
influenza vaccination safe during any stage of pregnancy. However, because
spontaneous abortion is common in the first trimester and unnecessary expo-
sures have traditionally been avoided during this time, some experts prefer
influenza vaccination during the second trimester to avoid coincidental associa-
tion of the vaccine with early pregancy loss.
Groups that Can Transmit Influenza to Persons at High Risk
Persons who are clinically or subclinically infected can transmit influenza virus to
persons at high risk that they care for or live with. Some persons at high risk (e.g., the
elderly, transplant recipients, and persons with AIDS) can have a low antibody re-
sponse to influenza vaccine. Efforts to protect these members of high-risk groups
against influenza might be improved by reducing the likelihood of influenza exposure
from their caregivers. Therefore, the following groups should be vaccinated:
• physicians, nurses, and other personnel in both hospital and outpatient-care
settings;
• employees of nursing homes and chronic-care facilities who have contact with
patients or residents;
• providers of home care to persons at high risk (e.g., visiting nurses and volunteer
workers); and
• household members (including children) of persons in high-risk groups.
VACCINATION OF OTHER GROUPS
Persons Infected with Human Immunodeficiency Virus
Limited information exists regarding the frequency and severity of influenza ill-
ness among human immunodeficiency virus (HIV)-infected persons, but reports
suggest that symptoms might be prolonged and the risk for complications increased
for some HIV-infected persons. Influenza vaccine has produced protective antibody
titers against influenza in vaccinated HIV-infected persons who have minimal AIDS-
related symptoms and high CD4+ T-lymphocyte cell counts. In patients who have ad-
vanced HIV disease and low CD4+ T-lymphocyte cell counts, however, influenza
vaccine may not induce protective antibody titers; a second dose of vaccine does not
improve the immune response for these persons.
Recent studies have examined the effect of influenza vaccination on replication of
HIV type 1 (HIV-1). Although some studies have demonstrated a transient (i.e., 2- to
4-week) increase in replication of HIV-1 in the plasma or peripheral blood mononu-
clear cells of HIV-infected persons after vaccine administration, other studies using
similar laboratory techniques have not indicated any substantial increase in replica-
tion. Deterioration of CD4+ T-lymphocyte cell counts and progression of clinical HIV
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disease have not been demonstrated among HIV-infected persons who receive
vaccine. Because influenza can result in serious illness and complications and because
influenza vaccination may result in protective antibody titers, vaccination will benefit
many HIV-infected patients.
Breastfeeding Mothers
Influenza vaccine does not affect the safety of breastfeeding for mothers or infants.
Breastfeeding does not adversely affect immune response and is not a contraindica-
tion for vaccination.
Persons Traveling to Foreign Countries
The risk for exposure to influenza during travel to foreign countries varies, depend-
ing on season and destination. In the tropics, influenza can occur throughout the year;
in the Southern Hemisphere, most activity occurs from April through September. Be-
cause of the short incubation period for influenza, exposure to the virus during travel
can result in clinical illness that begins while traveling, which is an inconvenience or
potential danger, especially for persons at increased risk for complications. Persons
preparing to travel to the tropics at any time of year or to the Southern Hemisphere
from April through September should review their influenza vaccination histories. If
they were not vaccinated the previous fall or winter, they should consider influenza
vaccination before travel. Persons in high-risk groups should be especially encour-
aged to receive the most current vaccine. Persons at high risk who received the
previous season’s vaccine before travel should be revaccinated in the fall or winter
with the current vaccine.
General Population
Physicians should administer influenza vaccine to any person who wishes to
reduce the likelihood of becoming ill with influenza. Persons who provide essential
community services should be considered for vaccination to minimize disruption of
essential activities during influenza outbreaks. Students or other persons in institu-
tional settings (e.g., those who reside in dormitories) should be encouraged to receive
vaccine to minimize the disruption of routine activities during epidemics.
PERSONS WHO SHOULD NOT BE VACCINATED
Inactivated influenza vaccine should not be administered to persons known to have
anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine
without first consulting a physician (see Side Effects and Adverse Reactions). Use of
an antiviral agent (i.e., amantadine or rimantadine) is an option for prevention of influ-
enza A in such persons. However, persons who have a history of anaphylactic
hypersensitivity to vaccine components but who are also at high risk for complica-
tions of influenza can benefit from vaccine after appropriate allergy evaluation and
desensitization. Specific information about vaccine components can be found in pack-
age inserts for each manufacturer.
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Adults with acute febrile illness usually should not be vaccinated until their
symptoms have abated. However, minor illnesses with or without fever should not
contraindicate the use of influenza vaccine, particularly among children with mild up-
per respiratory tract infection or allergic rhinitis.
SIDE EFFECTS AND ADVERSE REACTIONS
Because influenza vaccine contains only noninfectious viruses, it cannot cause
influenza. Respiratory disease after vaccination represents coincidental illness unre-
lated to influenza vaccination. The most frequent side effect of vaccination is soreness
at the vaccination site that lasts up to 2 days. These local reactions generally are mild
and rarely interfere with the ability to conduct usual daily activities. In addition, two
types of systemic reactions have occurred:
• Fever, malaise, myalgia, and other systemic symptoms can occur following vac-
cination and most often affect persons who have had no exposure to the
influenza virus antigens in the vaccine (e.g., young children). These reactions
begin 6–12 hours after vaccination and can persist for 1 or 2 days. Recent pla-
cebo-controlled trials suggest that in elderly persons and healthy young adults,
split-virus influenza vaccine is not associated with higher rates of systemic symp-
toms (e.g., fever, malaise, myalgia, and headache) when compared with placebo
injections.
• Immediate—presumably allergic—reactions (e.g., hives, angioedema, allergic
asthma, and systemic anaphylaxis) rarely occur after influenza vaccination.
These reactions probably result from hypersensitivity to some vaccine compo-
nent; most reactions likely are caused by residual egg protein. Although current
influenza vaccines contain only a small quantity of egg protein, this protein can
induce immediate hypersensitivity reactions among persons who have severe
egg allergy. Persons who have developed hives, have had swelling of the lips or
tongue, or have experienced acute respiratory distress or collapse after eating
eggs should consult a physician for appropriate evaluation to help determine if
vaccine should be administered. Persons who have documented immunoglobu-
lin E (IgE)-mediated hypersensitivity to eggs—including those who have had
occupational asthma or other allergic responses due to exposure to egg pro-
tein—might also be at increased risk for reactions from influenza vaccine, and
similar consultation should be considered. The protocol for influenza vaccination
developed by Murphy and Strunk may be considered for patients who have egg
allergies and medical conditions that place them at increased risk for influenza-
associated complications.
Hypersensitivity reactions to any vaccine component can occur. Although exposure
to vaccines containing thimerosal can lead to induction of hypersensitivity, most
patients do not develop reactions to thimerosal when administered as a component of
vaccines—even when patch or intradermal tests for thimerosal indicate hypersensitiv-
ity. When reported, hypersensitivity to thimerosal usually has consisted of local,
delayed-type hypersensitivity reactions.
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Unlike the 1976 swine influenza vaccine, subsequent vaccines prepared from other
virus strains have not been clearly associated with an increased frequency of Guillain-
Barré syndrome (GBS). However, obtaining a precise estimate of a small increase in
risk is difficult for a rare condition such as GBS, which has an annual background
incidence of only one to two cases per 100,000 adult population. During five of six
seasons studied since 1976, the point estimates of the relative risks of GBS after influ-
enza vaccination were slightly elevated; however, in none of these studies was the
overall elevation in relative risk statistically significant. In the two most recently stud-
ied seasons, the combined number of GBS cases peaked 2 weeks after vaccination.
Data from all of these studies suggest that if an increased relative risk does exist, it is
lower for persons aged ≥65 years than for those 18–64 years of age. The slight in-
crease in the point estimates of the relative risks and the increased number of cases in
the second week after vaccination may be the result of vaccination but also could be
due to other factors (e.g., confounding or diagnostic bias) rather than a true vaccine-
related  risk.
Among persons who received the swine influenza vaccine in 1976, the rate of GBS
that exceeded the background rate was slightly less than one case per 100,000 vacci-
nations. Even if GBS were a true side effect in subsequent years, the estimated risk for
GBS was much lower than 1:100,000 and substantially less than that for severe influ-
enza, which could be prevented by vaccination, especially for persons aged ≥65 years
and those who have medical indications for influenza vaccination. 
Whereas the incidence of GBS in the general population is very low, persons with a
history of GBS have a substantially greater likelihood of subsequently developing
GBS than persons without such a history. Thus, the likelihood of coincidentally devel-
oping GBS after influenza vaccination is expected to be greater among persons with a
history of GBS than among persons with no history of this syndrome. Whether influ-
enza vaccination might be causally associated with this risk for recurrence is not
known. Although avoiding a subsequent influenza vaccination in persons known to
have developed GBS within 6 weeks of a previous influenza vaccination seems pru-
dent, for most persons with a history of GBS who are at high risk for severe
complications from influenza the established benefits of influenza vaccination justify
yearly vaccination.
SIMULTANEOUS ADMINISTRATION OF OTHER VACCINES,
INCLUDING CHILDHOOD VACCINES
The target groups for influenza and pneumococcal vaccination overlap consider-
ably. For persons at high risk who have not previously been vaccinated with
pneumococcal vaccine, health-care providers should strongly consider administering
pneumococcal and influenza vaccines concurrently. Both vaccines can be adminis-
tered at the same time at different sites without increasing side effects. However,
influenza vaccine is administered each year, whereas pneumococcal vaccine is not.
Children at high risk for influenza-related complications can receive influenza vaccine
at the same time they receive other routine vaccinations, including pertussis vaccine
(DTaP or DTP). Because influenza vaccine can cause fever when administered to
young children, DTaP (which is less frequently associated with fever and other adverse
events) is preferable.
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TIMING OF INFLUENZA VACCINATION ACTIVITIES
Beginning each September (when vaccine for the upcoming influenza season
becomes available) persons at high risk who are seen by health-care providers for
routine care or as a result of hospitalization should be offered influenza vaccine. Op-
portunities to vaccinate persons at high risk for complications of influenza should not
be missed.
The optimal time for organized vaccination campaigns for persons in high-risk
groups is usually the period from October through mid-November. In the United
States, influenza activity generally peaks between late December and early March.
High levels of influenza activity infrequently occur in the contiguous 48 states before
December. Administering vaccine too far in advance of the influenza season should be
avoided in facilities such as nursing homes, because antibody levels might begin to
decline within a few months of vaccination. Vaccination programs can be undertaken
as soon as current vaccine is available if regional influenza activity is expected to be-
gin earlier than December.
Children aged <9 years who have not been vaccinated previously should receive
two doses of vaccine at least 1 month apart to maximize the likelihood of a satisfactory
antibody response to all three vaccine antigens. The second dose should be adminis-
tered before December, if possible. Vaccine should be offered to both children and
adults up to and even after influenza virus activity is documented in a community.
STRATEGIES FOR IMPLEMENTING INFLUENZA
VACCINE RECOMMENDATIONS
Successful vaccination programs have combined education for health-care work-
ers, publicity and education targeted toward potential recipients, a plan for identifying
persons at high risk (usually by medical-record review), and efforts to remove admin-
istrative and financial barriers that prevent persons from receiving the vaccine.
Persons for whom influenza vaccine is recommended can be identified and vaccinated
in the settings described in the following paragraphs.
Outpatient Clinics and Physicians’ Offices
Staff in physicians’ offices, clinics, health-maintenance organizations, and em-
ployee health clinics should be instructed to identify and label the medical records of
patients who should receive vaccine. Vaccine should be offered during visits begin-
ning in September and throughout the influenza season. The offer of vaccine and its
receipt or refusal should be documented in the medical record. Patients in high-risk
groups who do not have regularly scheduled visits during the fall should be reminded
by mail or telephone of the need for vaccine. If possible, arrangements should be
made to provide vaccine with minimal waiting time and at the lowest possible cost.
Facilities Providing Episodic or Acute Care
Health-care providers in these settings (e.g., emergency rooms and walk-in clinics)
should be familiar with influenza vaccine recommendations. They should offer vac-
cine to persons in high-risk groups or should provide written information on why,
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where, and how to obtain the vaccine. Written information should be available in lan-
guage(s) appropriate for the population served by the facility.
Nursing Homes and Other Residential
Long-Term–Care Facilities
Vaccination should be routinely provided to all residents of chronic-care facilities
with the concurrence of attending physicians rather than by obtaining individual vac-
cination orders for each patient. Consent for vaccination should be obtained from the
resident or a family member at the time of admission to the facility, and all resi-
dents should be vaccinated at one time, immediately preceding the influenza season.
Residents admitted during the winter months after completion of the vaccination pro-
gram should be vaccinated when they are admitted.
Acute-Care Hospitals
All persons aged ≥65 years and younger persons (including children) with high-risk
conditions who are hospitalized at any time from September through March should be
offered and strongly encouraged to receive influenza vaccine before they are dis-
charged. Household members and others with whom they will have contact should
receive written information about why and where to obtain influenza vaccine.
Outpatient Facilities Providing Continuing Care to Patients at
High Risk
All patients should be offered vaccine before the beginning of the influenza season.
Patients admitted to such programs (e.g., hemodialysis centers, hospital specialty-
care clinics, and outpatient rehabilitation programs) during the winter months after
the earlier vaccination program has been conducted should be vaccinated at the time
of admission. Household members should receive written information regarding the
need for vaccination and the places to obtain influenza vaccine.
Visiting Nurses and Others Providing Home Care to Persons at
High Risk
Nursing-care plans should identify patients in high-risk groups, and vaccine should
be provided in the home if necessary. Caregivers and other persons in the household
(including children) should be referred for vaccination.
Facilities Providing Services to Persons Aged ≥65 Years
In these facilities (e.g., retirement communities and recreation centers), all unvacci-
nated residents/attendees should be offered vaccine on site before the influenza
season. Education/publicity programs also should be provided; these programs
should emphasize the need for influenza vaccine and provide specific information
concerning how, where, and when to obtain it.
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Clinics and Others Providing Health Care for Travelers
Indications for influenza vaccination should be reviewed before travel. Vaccine
should be offered, if appropriate (see Travelers to Foreign Countries).
Health-Care Workers
Administrators of all health-care facilities should arrange for influenza vaccine to be
offered to all personnel before the influenza season. Personnel should be provided
with appropriate educational materials and strongly encouraged to receive vaccine.
Particular emphasis should be placed on vaccination of persons who care for
members of high-risk groups (e.g., staff of intensive-care units [including newborn
intensive-care units], staff of medical/surgical units, and employees of nursing homes
and chronic-care facilities). Using a mobile cart to take vaccine to hospital wards or
other work sites and making vaccine available during night and weekend work shifts
can enhance compliance, as can a follow-up campaign early in the course of a com-
munity outbreak.
ANTIVIRAL AGENTS FOR INFLUENZA A
The two antiviral agents with specific activity against influenza A viruses are aman-
tadine hydrochloride and rimantadine hydrochloride. These chemically related drugs
interfere with the replication cycle of type A (but not type B) influenza viruses. When
administered prophylactically to healthy adults or children before and throughout the
epidemic period, both drugs are approximately 70%–90% effective in preventing
illness caused by naturally occurring strains of type A influenza viruses. Because an-
tiviral agents taken prophylactically can prevent illness but not subclinical infection,
some persons who take these drugs can still develop immune responses that will pro-
tect them when they are exposed to antigenically related viruses in later years.
In otherwise healthy adults, amantadine and rimantadine can reduce the severity
and duration of signs and symptoms of influenza A illness when administered within
48 hours of illness onset. Studies evaluating the efficacy of treatment for children
with either amantadine or rimantadine are limited. Amantadine was approved for
treatment and prophylaxis of all influenza type A virus infections in 1976. Although
few placebo-controlled studies were conducted to determine the efficacy of aman-
tadine treatment among children before approval, amantadine is indicated for
treatment and prophylaxis of adults and children aged ≥1 year. Rimantadine was ap-
proved in 1993 for treatment and prophylaxis in adults but was approved only for
prophylaxis in children. Further studies might provide the data needed to support fu-
ture approval of rimantadine treatment in this age group.
As with all drugs, amantadine and rimantadine can cause adverse reactions in
some persons. Such adverse reactions rarely are severe; however, for some catego-
ries of patients, severe adverse reactions are more likely to occur. Amantadine has
been associated with a higher incidence of adverse central nervous system (CNS)
reactions than rimantadine (see Considerations for Selecting Amantadine or Riman-
tadine for Chemoprophylaxis or Treatment).
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RECOMMENDATIONS FOR THE USE OF AMANTADINE
AND RIMANTADINE
Use as Prophylaxis
Chemoprophylaxis is not a substitute for vaccination. Recommendations for
chemoprophylaxis are provided primarily to help health-care providers make deci-
sions regarding persons who are at greatest risk for severe illness and complications
if infected with influenza A virus.
When amantadine or rimantadine is administered as prophylaxis, factors such as
cost, compliance, and potential side effects should be considered when determining
the period of prophylaxis. To be maximally effective as prophylaxis, the drug must be
taken each day for the duration of influenza activity in the community. However, to be
most cost effective, amantadine or rimantadine prophylaxis should be taken only dur-
ing the period of peak influenza activity in a community.
Persons at High Risk Vaccinated After
Influenza A Activity Has Begun
Persons at high risk still can be vaccinated after an outbreak of influenza A has
begun in a community. However, the development of antibodies in adults after vacci-
nation can take as long as 2 weeks, during which time chemoprophylaxis should be
considered. Children who receive influenza vaccine for the first time can require as
long as 6 weeks of prophylaxis (i.e., prophylaxis for 2 weeks after the second dose of
vaccine has been received). Amantadine and rimantadine do not interfere with the
antibody response to the vaccine.
Persons Providing Care to Those at High Risk
To reduce the spread of virus to persons at high risk, chemoprophylaxis may be
considered during community outbreaks for a) unvaccinated persons who have
frequent contact with persons at high risk (e.g., household members, visiting nurses,
and volunteer workers) and b) unvaccinated employees of hospitals, clinics, and
chronic-care facilities. For those persons who cannot be vaccinated, chemoprophy-
laxis during the period of peak influenza activity may be considered. For those persons
who receive vaccine at a time when influenza A is present in the community, chemo-
prophylaxis can be administered for 2 weeks after vaccination. Prophylaxis should be
considered for all employees, regardless of their vaccination status, if the outbreak is
caused by a variant strain of influenza A that might not be controlled by the vaccine.
Persons Who Have Immune Deficiency
Chemoprophylaxis might be indicated for persons at high risk who are expected to
have an inadequate antibody response to influenza vaccine. This category includes
persons who have HIV infection, especially those who have advanced HIV disease. No
data are available concerning possible interactions with other drugs used in the man-
agement of patients who have HIV infection. Such patients should be monitored
closely if amantadine or rimantadine chemoprophylaxis is administered.
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Persons for Whom Influenza Vaccine Is Contraindicated
Chemoprophylaxis throughout the influenza season or during peak influenza activ-
ity might be appropriate for persons at high risk who should not be vaccinated.
Influenza vaccine may be contraindicated in persons who have severe anaphylactic
hypersensitivity to egg protein or other vaccine components.
Other Persons
Amantadine or rimantadine also can be administered prophylactically to anyone
who wishes to avoid influenza A illness. The health-care provider and patient should
make this decision on an individual basis.
Use of Antivirals as Therapy
Amantadine and rimantadine can reduce the severity and shorten the duration of
influenza A illness among healthy adults when administered within 48 hours of illness
onset. Whether antiviral therapy will prevent complications of influenza type A among
persons at high risk is unknown. Insufficient data exist to determine the efficacy of
rimantadine treatment in children. Thus, rimantadine is currently approved only for
prophylaxis in children, but it is not approved for treatment in this age group.
Amantadine- and rimantadine-resistant influenza A viruses can emerge when
either of these drugs is administered for treatment; amantadine-resistant strains are
cross-resistant to rimantadine and vice versa. Both the frequency with which resistant
viruses emerge and the extent of their transmission are unknown, but data indicate
that amantadine- and rimantadine-resistant viruses are no more virulent or transmis-
sible than amantadine- and rimantadine-sensitive viruses. 
The screening of naturally occurring epidemic strains of influenza type A has rarely
detected amantadine- and rimantadine-resistant viruses. Resistant viruses have most
frequently been isolated from persons taking one of these drugs as therapy for influ-
enza A infection. Resistant viruses have been isolated from persons who live at home
or in an institution where other residents are taking or have recently taken amantadine
or rimantadine as therapy. Persons who have influenza-like illness should avoid
contact with uninfected persons as much as possible, regardless of whether they are
being treated with amantadine or rimantadine. Persons who have influenza type A
infection and who are treated with either drug can shed amantadine- or rimantadine-
sensitive viruses early in the course of treatment, but can later shed drug-resistant
viruses, especially after 5–7 days of therapy. Such persons can benefit from therapy
even when resistant viruses emerge; however, they also can transmit infection to
other persons with whom they come in contact. Because of possible induction of
amantadine or rimantadine resistance, treatment of persons who have influenza-like
illness should be discontinued as soon as clinically warranted, generally after 3–5 days
of treatment or within 24–48 hours after the disappearance of signs and symptoms.
Laboratory isolation of influenza viruses obtained from persons who are receiving
amantadine or rimantadine should be reported to CDC through state health depart-
ments, and the isolates should be sent to CDC for antiviral sensitivity testing.
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Outbreak Control in Institutions
When confirmed or suspected outbreaks of influenza A occur in institutions that
house persons at high risk, chemoprophylaxis should be started as early as possible
to reduce the spread of the virus. Contingency planning is needed to ensure rapid
administration of amantadine or rimantadine to residents. This planning should in-
clude preapproved medication orders or plans to obtain physicians’ orders on short
notice. When amantadine or rimantadine is used for outbreak control, the drug should
be administered to all residents of the institution—regardless of whether they re-
ceived influenza vaccine the previous fall. The drug should be continued for at least
2 weeks or until approximately 1 week after the end of the outbreak. The dose for each
resident should be determined after consulting the dosage recommendations and
precautions (see Considerations for Selecting Amantadine or Rimantadine for Chemo-
prophylaxis or Treatment) and the manufacturer’s package insert. To reduce the
spread of virus and to minimize disruption of patient care, chemoprophylaxis also can
be offered to unvaccinated staff who provide care to persons at high risk. Prophylaxis
should be considered for all employees, regardless of their vaccination status, if the
outbreak is caused by a variant strain of influenza A that is not controlled by the
vaccine.
Chemoprophylaxis also may be considered for controlling influenza A outbreaks in
other closed or semi-closed settings (e.g., dormitories or other settings where persons
live in close proximity). To reduce the spread of infection and the chances of prophy-
laxis failure resulting from transmission of drug-resistant virus, measures should be
taken to reduce contact as much as possible between persons on chemoprophylaxis
and those taking drug for treatment. 
CONSIDERATIONS FOR SELECTING AMANTADINE
OR RIMANTADINE FOR CHEMOPROPHYLAXIS
OR TREATMENT
Side Effects/Toxicity
Despite the similarities between the two drugs, amantadine and rimantadine differ
in their pharmacokinetic properties. More than 90% of amantadine is excreted
unchanged, whereas approximately 75% of rimantadine is metabolized by the liver.
However, both drugs and their metabolites are excreted by the kidneys.
The pharmacokinetic differences between amantadine and rimantadine might
explain differences in side effects. Although both drugs can cause CNS and gastroin-
testinal side effects when administered to young, healthy adults at equivalent dosages
of 200 mg/day, the incidence of CNS side effects (e.g., nervousness, anxiety, difficulty
concentrating, and lightheadedness) is higher among persons taking amantadine
compared with those taking rimantadine. In a 6-week study of prophylaxis in healthy
adults, approximately 6% of participants taking rimantadine at a dose of 200 mg/day
experienced at least one CNS symptom, compared with approximately 14% of those
taking the same dose of amantadine and 4% of those taking placebo. The incidence of
gastrointestinal side effects (e.g., nausea and anorexia) is approximately 3% among
persons taking either drug, compared with 1%–2% among persons receiving the pla-
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cebo. Side effects associated with both drugs are usually mild and cease soon after
discontinuing the drug. Side effects can diminish or disappear after the first week de-
spite continued drug ingestion. However, serious side effects have been observed
(e.g., marked behavioral changes, delirium, hallucinations, agitation, and seizures).
These more severe side effects have been associated with high plasma drug concen-
trations and have been observed most often among persons who have renal
insufficiency, seizure disorders, or certain psychiatric disorders and among elderly
persons who have been taking amantadine as prophylaxis at a dose of 200 mg/day.
Clinical observations and studies have indicated that lowering the dosage of aman-
tadine among these persons reduces the incidence and severity of such side effects,
and recommendations for reduced dosages for these groups of patients have been
made. Because rimantadine has been marketed for a shorter period of time than
amantadine, its safety in certain patient populations (e.g., chronically ill and elderly
persons) has been evaluated less frequently. Clinical trials of rimantadine have more
commonly involved young, healthy persons. 
Providers should review the package insert before using amantadine or riman-
tadine for any patient. The patient’s age, weight, and renal function; the presence of
other medical conditions; the indications for use of amantadine or rimantadine (i.e.,
prophylaxis or therapy); and the potential for interaction with other medications must
be considered, and the dosage and duration of treatment must be adjusted appropri-
ately. Modifications in dosage might be required for persons who have impaired
renal or hepatic function, the elderly, children, and persons with a history of seizures
(Table 2). The following are guidelines for the use of amantadine and rimantadine in
certain patient populations.
Persons Who Have Impaired Renal Function
Amantadine
 Amantadine is excreted unchanged in the urine by glomerular filtration and tubu-
lar secretion. Thus, renal clearance of amantadine is reduced substantially in persons
with renal insufficiency. A reduction in dosage is recommended for patients with
creatinine clearance ≤50 mL/min/1.73m2. Guidelines for amantadine dosage based on
creatinine clearance are found in the packet insert. However, because recommended
dosages based on creatinine clearance might provide only an approximation of the
optimal dose for a given patient, such persons should be observed carefully so that
adverse reactions can be recognized promptly and either the dose can be further
reduced or the drug can be discontinued, if necessary. Hemodialysis contributes mini-
mally to drug clearance.
Rimantadine
 The safety and pharmacokinetics of rimantadine among patients with renal insuf-
ficiency have been evaluated only after single-dose administration. Further studies are
needed to determine the multiple-dose pharmacokinetics and the most appropriate
dosages for these patients.
In a single-dose study of patients with anuric renal failure, the apparent clearance
of rimantadine was approximately 40% lower, and the elimination half-life was
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approximately 1.6-fold greater than that in healthy controls of the same age. Hemodia-
lysis did not contribute to drug clearance. In studies among persons with less severe
renal disease, drug clearance was also reduced, and plasma concentrations were
higher compared with control patients without renal disease who were the same
weight, age, and sex.
A reduction in dosage to 100 mg/day is recommended for persons with creatinine
clearance ≤10 mL/min. Because of the potential for accumulation of rimantadine and
its metabolites, patients with any degree of renal insufficiency, including elderly
persons, should be monitored for adverse effects, and either the dosage should be
reduced or the drug should be discontinued, if necessary. 




1–9 10–13 14–64 ≥65
Amantadine*
 Treatment 5 mg/kg/day








 Prophylaxis 5 mg/kg/day









 Treatment NA NA 100 mg
twice daily
100 or 200** mg/day
 Prophylaxis 5 mg/kg/day







100 or 200** mg/day
 *Amantadine manufacturers include: Dupont Pharma (Symmetrel®—syrup); Solvay
Pharmaceuticals (Symadine —capsule); Chase Pharmaceuticals and Invamed (Amantadine
HCL—capsule); and Copley Pharmaceuticals, Barre National, and Mikart (Amantadine
HCL—syrup). Rimantadine is manufactured by Forest Laboratories (Flumandine®—tablet
and syrup). The drug package insert should be consulted for dosage recommendations for
administering amantadine to persons with creatinine clearance ≤50 mL/min/1.73m2.
 †5 mg/kg of amantadine or rimantadine syrup = 1 tsp/22 lbs.
 §Children aged ≥10 years who weigh <40 kg should be administered amantadine or
rimantadine at a dose of 5 mg/kg/day.
 ¶A reduction in dose to 100 mg/day of rimantadine is recommended for persons who have
severe hepatic dysfunction or those with creatinine clearance ≤10 mL/min. Other persons
with less severe hepatic or renal dysfunction taking >100 mg/day of rimantadine should be
observed closely, and the dosage should be reduced or the drug discontinued, if necessary.
**Elderly nursing-home residents should be administered only 100 mg/day of rimantadine. A
reduction in dose to 100 mg/day should be considered for all persons aged ≥65 years if
they experience possible side effects when taking 200 mg/day.
NA=Not applicable.
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Persons Aged ≥65 Years
Amantadine
Because renal function declines with increasing age, the daily dose for persons
aged ≥65 years should not exceed 100 mg for prophylaxis or treatment. For some eld-
erly persons, the dose should be further reduced. Studies suggest that because of
their smaller average body size, elderly women are more likely than elderly men to
experience side effects at a daily dose of 100 mg.
Rimantadine
The incidence and severity of CNS side effects among elderly persons appear to be
substantially lower among those taking rimantadine at a dose of 200 mg/day com-
pared with elderly persons taking the same dose of amantadine. However, when
rimantadine has been administered at a dosage of 200 mg/day to chronically ill elderly
persons, they have had a higher incidence of CNS and gastrointestinal symptoms
than healthy, younger persons taking rimantadine at the same dosage. After long-
term administration of rimantadine at a dosage of 200 mg/day, serum rimantadine
concentrations among elderly nursing-home residents have been twofold to fourfold
greater than those reported in younger adults.
The dosage of rimantadine should be reduced to 100 mg/day for treatment or pro-
phylaxis of elderly nursing-home residents. Although further studies are needed to
determine the optimal dose for other elderly persons, a reduction in dosage to
100 mg/day should be considered for all persons aged ≥65 years if they experience
signs and symptoms that might represent side effects when taking a dosage of
200 mg/day.
Persons Who Have Liver Disease
Amantadine
No increase in adverse reactions to amantadine has been observed among persons
who have liver disease. Rare instances of reversible elevation of liver enzymes have
been reported in patients receiving amantadine, although a specific relationship be-
tween the drug and such changes has not been established.
Rimantadine
The safety and pharmacokinetics of rimantadine only have been evaluated after
single-dose administration. In a study of persons with chronic liver disease (most with
stabilized cirrhosis), no alterations were observed after a single dose. However, in per-
sons with severe liver dysfunction, the apparent clearance of rimantadine was 50%
lower than that reported for persons without liver disease. A dose reduction to
100 mg/day is recommended for persons with severe hepatic dysfunction.
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Persons Who Have Seizure Disorders
Amantadine
An increased incidence of seizures has been reported in patients with a history of
seizure disorders who have received amantadine. Patients with seizure disorders
should be observed closely for possible increased seizure activity when taking
amantadine.
Rimantadine
In clinical trials, seizures (or seizure-like activity) have been observed in a few per-
sons with a history of seizures who were not receiving anticonvulsant medication
while taking rimantadine. The extent to which rimantadine might increase the inci-
dence of seizures among persons with seizure disorders has not been adequately
evaluated, because such persons usually have been excluded from participating in
clinical trials of rimantadine.
Children
Amantadine
The use of amantadine in children aged <1 year has not been adequately evaluated.
The FDA-approved dosage for children aged 1–9 years is 4.4–8.8 mg/kg/day, not to
exceed 150 mg/day. Although further studies to determine the optimal dosage for chil-
dren are needed, physicians should consider prescribing only 5 mg/kg/day (not to
exceed 150 mg/day) to reduce the risk for toxicity. The approved dosage for children
aged ≥10 years is 200 mg/day; however, for children weighing <40 kg, prescribing
5 mg/kg/day, regardless of age, is advisable. 
Rimantadine
The use of rimantadine in children aged <1 year has not been adequately evalu-
ated. In children aged 1–9 years, rimantadine should be administered in one or two
divided doses at a dosage of 5 mg/kg/day, not to exceed 150 mg/day. The approved
dosage for children aged ≥10 years is 200 mg/day (100 mg twice a day); however,




Careful observation is advised when amantadine is administered concurrently with
drugs that affect the CNS, especially CNS stimulants. Concomitant administration of
antihistamines or anticholinergic drugs may increase the incidence of adverse CNS
reactions.
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Rimantadine
No clinically significant interactions between rimantadine and other drugs have
been identified. For more detailed information concerning potential drug interactions
for either drug, the package insert should be consulted.
SOURCES OF INFORMATION ON INFLUENZA-CONTROL
PROGRAMS
Information regarding influenza surveillance is available through the CDC Voice In-
formation System (influenza update), telephone (404) 332-4551, or through the CDC
Information Service on the Public Health Network electronic bulletin board. From Oc-
tober through May, the information is updated at least every other week. In addition,
periodic updates about influenza are published in the weekly MMWR. State and local
health departments should be consulted regarding availability of influenza vaccine,
access to vaccination programs, and information about state or local influenza activity.
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